The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 11, 2019

Filed:

Jan. 15, 2016
Applicant:

Roche Glycart Ag, Schlieren, CH;

Inventors:

Oliver Ast, Bassersdorf, CH;

Peter Bruenker, Hittnau, CH;

Thomas U. Hofer, Zurich, CH;

Ralf Hosse, Cham, CH;

Christian Klein, Bonstetten, CH;

Ekkehard Moessner, Kreuzlingen, CH;

Pablo Umana, Wollerau, CH;

Assignee:

ROCHE GLYCART AG, Schlieren, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/55 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C07K 14/54 (2006.01); C07K 16/18 (2006.01); C07K 16/30 (2006.01); A61K 38/20 (2006.01); C07K 16/46 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 14/52 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A61K 38/2013 (2013.01); A61K 47/6813 (2017.08); A61K 47/6843 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6853 (2017.08); C07K 14/5434 (2013.01); C07K 14/55 (2013.01); C07K 16/18 (2013.01); C07K 16/283 (2013.01); C07K 16/2866 (2013.01); C07K 16/30 (2013.01); C07K 16/3007 (2013.01); C07K 16/46 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); C07K 14/52 (2013.01); C07K 2317/21 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/71 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01);
Abstract

The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.


Find Patent Forward Citations

Loading…